NEXGEL Ousts CEO, Launches Strategic Review Amid Going Concern Crisis
NXGL sits 29% above its 52-week low of $0.3.
Summary
NEXGEL replaced CEO Adam Levy with Brian Kieser effective August 21, 2026, and formed a Special Committee to review strategic alternatives, capital structure, and liquidity. This follows a going concern warning in the Q2 10-Q, potential defaults on $13.9M in convertible notes, material weaknesses in internal controls, and a rejected share increase proposal. The board is signaling a potential restructuring or asset divestiture, with the committee expected to present a framework within 30-45 days. The company's market cap is under $5 million, making this a high-stakes turnaround attempt. Watch for the committee's recommendations and any update on the reverse stock split proposal filed August 14.
At the time of this announcement, NXGL was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.30 to $2.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.